Lupus & antiphospholipid syndrome
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus
Authors' conclusion
Anti-Ro positivity is associated with higher disease activity and increased treatment needs. Ro positivity correlates with laboratory abnormalities such as hypocomplementemia and leucopenia.
Study context
- Population
- Patients fulfilling systemic lupus erythematosus (SLE) classification criteria47.2% Ro+
- Participants
- 409 patients
- Exposure
- Ro+ vs Ro-negative SLE
- Outcome
- High Disease Activity Status (HDAS) (ever SLEDAI-2K ≥10), AMS and time-adjusted mean clinical SLEDAI
Methodological detailslinear or logistic regressions, multivariate analysis
- Linear or logistic regressions
- Multivariate analysis
Main finding
As reported in the abstract
Disease activity: HDAS (ever SLEDAI2K ≥10) and AMS >4
Ro+
47.2%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Sicca symptoms in Ro+ patients | Ro+ 24.4% |
Sicca symptoms in Ro+ patients
- Hypergammaglobulinemia significantly more common
Factors linked to Ro positivity (multivariate analysis)
- Asian ethnicity, severe flares, adjusted mean SLEDAI (AMS), hypocomplementemia, RF, proteinuria, leucopenia and sicca symptoms significantly linked to Ro positivity
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus. Rheumatology (Oxford). Published 14 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →